SAGE Therapeutics Inc Q3 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: George Farmer - Scotiabank Global Banking and Markets, Research Division - Analyst : Just wondering if you could go into some detail about what the diagnostic criteria are going to be in order for pre auth to get approved. It seems to me it was such an expensive drug that one would want to differentiate, say, from just general baby blues to follow-on diagnostic -- diagnosed PPD. Can you speak to that?

Question: George Farmer - Scotiabank Global Banking and Markets, Research Division - Analyst : So it will be just as simple as that, just to check the box diagnosis?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : It's nice to see that ZURZUVAE will be able available for patients in the near future here. So we went through the review documents for ZURZUVAE and we're looking specifically at the post-marketing requirements and commitments. Do you expect these studies, especially the nonclinical safety study to have the potential to make any adjustments in the language of the label as it stands today? And would those have any bearing on your potential ability to still pursue zuranolone for major depressive disorder?